Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?

By Ohno Shinji  

Breast Cancer, Vol. 19, Iss. 3, 2012-07 ,pp. : 212-217

Springer Publishing Company

Access to resources Recommend Favorite

Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?

By Galimberti Viviana  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 819-825

Springer Publishing Company

Access to resources Recommend Favorite

Can Patients' Likelihood of Benefiting from Primary Chemotherapy for Breast Cancer Be Predicted Before Commencement of Treatment?

By Ogston Keith   Miller Iain   Schofield Andrew   Spyrantis Andreas   Pavlidou Eleni   Sarkar Tarun   Hutcheon Andrew   Payne Simon   Heys Steven  

Breast Cancer Research and Treatment, Vol. 86, Iss. 2, 2004-07 ,pp. : 181-189

Springer Publishing Company

Access to resources Recommend Favorite

A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer

By Coleman R.E.   Houston S.   Purohit O.P.   Rubens R.D.   Kandra A.   Ford J.  

European Journal of Cancer, Vol. 34, Iss. 6, 1998-05 ,pp. : 820-824

Elsevier

Access to resources Recommend Favorite

Which is better in neoadjuvant treatment of breast cancer? Taxane followed by anthracyline or vice versa

By Altundag Kadri   Altundag Ozden   Baptista Mauricio   Atik Mustafa  

Breast Cancer Research and Treatment, Vol. 97, Iss. 2, 2006-05 ,pp. : 221-221

Springer Publishing Company

Access to resources Recommend Favorite